Moderna, Inc. (MRNA) stock soared 5% in pre-market trading on Wednesday, building on the positive momentum from the previous session and boosted by news of the CEO's significant stock purchase.
On Tuesday, Moderna's shares surged 5.04% in after-hours trading, defying expectations after an analyst at Redburn Atlantic lowered its price target on the pharmaceutical company's stock. Despite the downward revision, which suggested potentially weaker expectations for Moderna's future performance or valuation, investors seemed undeterred and pushed the stock higher.
Further fueling the pre-market rally was the revelation that Moderna's CEO, Stephane Bancel, had made open market purchases totaling approximately $5 million, acquiring 160,314 shares of the company's common stock. This significant investment by the top executive reflects Bancel's continued confidence in Moderna's future prospects as the company continues to innovate within the life sciences sector.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。